Industry News
Victorians get $60 million for innovation infrastructure
The Victorian State Government will fund another round of the Science Technology Innovation Infrastructure Grants program (STII), providing $60 million to supports biomedical, environmental, agricultural, manufacturing and ICT infrastructure projects. [ + ]
AustCancer snaps up US vaccine developer
Australian Cancer Technologies (AustCancer, ASX: ACU) is the latest Australian company to announce an acquisition of a US company, with its proposal to acquire US vaccine developer Galenica Pharmaceuticals for around US$5 million in shares. [ + ]
The GM ban: what it will mean for plant biotech
The future of the Victorian wheat industry has moved from a biosecure glasshouse into a small, netted field plot at the International Centre for Cereal Breeding (CIMMYT) in Mexico. [ + ]
Political science: behind the GM ban
Almost two months ago, the Victorian Labor government stunned the state's biotechnology industry by imposing a four-year, legislated moratorium on genetically modified (GM) canola cropping. [ + ]
Living Cell Technologies issues prospectus for $7 million ASX listing
Cell therapeutics company Living Cell Technologies has issued a prospectus to raise almost AUD$7 million through both a rights issue and a general issue. [ + ]
Independent trial affirms potential of Chemeq’s antimicrobial
An independent trial of the polymeric antimicrobial developed by Perth pharmaceutical company Chemeq (ASX:CMQ) has confirmed the drug’s potential to improve disease control in the poultry industry, while transforming its knife-edge economics. [ + ]
Regenera to list in early June
The CEO of Perth-based biotech Regenera, Tony Fitzgerald, said today that he expected the company’s offer to close next week, oversubscribed, ready for a June listing. [ + ]
XCeed lists on ASX at a premium
Xceed Biotechnology has listed on the ASX (ASX: XBL) at a premium to its placement price of AUD$0.20. At the time of writing the telco turned biotech company, was trading at $0.26, down almost 20 per cent from its opening price of $0.30. [ + ]
Anadis to supply nutraceutical to Chinese military
Melbourne biotech Anadis Limited (ASX:ANX) has announced the first sale to China of its bovine colostrum-based nutraceutical – a 3-tonne consignment destined to be used as a health food by the Chinese military and other agencies, to build immunity to enteric diseases. [ + ]
Brains for hire: Bio21 supports undergraduate lab-jobs program
The Undergraduate Research Opportunities Program (UROP) has been re-launched as a Bio21 initiative following the receipt of $90,000 over three years from the Victorian State government Department of Industry, Innovation and Regional Development's Office of Science and Technology for the program. [ + ]
Fighting sheep worms with genomics
Leading-edge technology is being used by two CSIRO Livestock Industries' research teams to identify genes that enable sheep to resist intestinal parasites.
[ + ]BioIT: EBI launches genome reviews database
The European Bioinformatics Institute (EBI) has launched Genome Reviews 1.0, a standardised resource for completely sequenced genomes, consisting of 256 chromosomes and plasmids, representing the complete genomes of 153 prokaryotic organisms. [ + ]
Human Genetic Signatures acquires Danish technology
Human Genetic Signatures has acquired the intellectual property and activities relating to intercalating nucleic acids (INAs) from Unest, a Danish company it helped to found. [ + ]
New BIF funding up for grabs
An undisclosed amount of new funding will be made available under the sixth round of the federal Biotechnology Innovation Fund (BIF), newly rebadged as part of the $1 billion, five-year Commercial Ready program. [ + ]
Dynamic Hearing licenses software to Germany’s Interton
Hearing aid software developer Dynamic Hearing has entered into a licensing agreement with German hearing aid manufacturer Interton Hoergeraete. [ + ]
